171 filings
Page 5 of 9
8-K
orinwfshlyag0 yy
22 Apr 16
Termination of a Material Definitive Agreement
12:00am
8-K
8n1xa pek
15 Apr 16
Synta Pharmaceuticals Conference Call
12:00am
8-K
1ra0zixso qi
14 Apr 16
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
2dujh42ryz8lw4 7pw
14 Apr 16
Synta Pharmaceuticals/Madrigal Pharmaceuticals Merger Announcement
12:00am
8-K
3o4z44n
1 Mar 16
Cost Associated with Exit or Disposal Activities
12:00am
8-K
gyfhue
9 Dec 15
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
cjn2o0 krpij
5 Nov 15
Cost Associated with Exit or Disposal Activities
12:00am
8-K
0fccp z9487811h5wy
22 Oct 15
Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer
12:00am
8-K
1ze5u2ptdhmemtt
16 Oct 15
Entry into a Material Definitive Agreement
12:00am
8-K
jmac9v1ryhjix2hi
15 Jun 15
Departure of Directors or Certain Officers
12:00am
8-K
00wd13bi30f90
27 Apr 15
Synta Announces Chen Schor Named President, Chief Executive Officer and Director
12:00am
8-K
bywj3j k43g42z
6 Apr 15
Synta Pharmaceuticals Closes Public Offering of Common Stock
12:00am
8-K
g6136xiqgxp28ob
1 Apr 15
Synta Pharmaceuticals Prices Public Offering of Common Stock
12:00am
8-K
m7k0a 2hf
6 Mar 15
Departure of Directors or Certain Officers
12:00am
8-K
y16mptmgc02q7qfiy
5 Feb 15
Synta Outlines New Corporate Strategy
12:00am
8-K
k9eka
4 Dec 14
Departure of Directors or Certain Officers
12:00am
8-K
ps2yqd zt
6 Aug 14
Synta Names Anne Whitaker Chief Executive Officer
12:00am
8-K
wj2tmyrepisxit
21 Jul 14
Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS
12:00am
8-K
znt1 n25z1dpc
18 Jul 14
Entry into a Material Definitive Agreement
12:00am
8-K
2kuye476e69mh7sw
27 Jun 14
Departure of Directors or Certain Officers
12:00am